We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+15.57%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$759M
AUM Growth
+$1.33M
Cap. Flow
-$40.4M
Cap. Flow %
-5.32%
Top 10 Hldgs %
61.45%
Holding
63
New
9
Increased
18
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$23.3M
2
IRON icon
Disc Medicine
IRON
+$15.3M
3
CATX icon
Perspective Therapeutics
CATX
+$14.7M
4
MGTX icon
MeiraGTx Holdings
MGTX
+$13.2M
5
QTTB icon
Q32 Bio
QTTB
+$4.95M

Top Sells

Rank Stock Value
1
HROW icon
Harrow
HROW
+$47.2M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$20.1M
3
CGON icon
CG Oncology
CGON
+$17.9M
4
ALKS icon
Alkermes
ALKS
+$13.7M
5
OCUL icon
Ocular Therapeutix
OCUL
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Miscellaneous 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLX icon
51
Protalix BioTherapeutics
PLX
$210M
$738K 0.1%
340,000
-2,138,176
-86% -$5.31M
BBOT
52
BridgeBio Oncology
BBOT
$736M
$477K 0.06%
+53,282
New +$572K
LBRX
53
LB Pharmaceuticals
LBRX
$1.54B
$358K 0.05%
+14,506
New +$335K
ADGM
54
Adagio Medical Holdings
ADGM
$11.6M
$21.2K ﹤0.01%
18,444
– –
ALKS icon
55
Alkermes
ALKS
$8.2B
– –
-490,000
Closed -$13.7M
BBIO icon
56
BridgeBio Pharma
BBIO
$15.4B
– –
-18,319
Closed -$1.4M
GBIO
57
DELISTED
Generation Bio
GBIO
– –
-310,000
Closed -$1.76M
GOSS icon
58
Gossamer Bio
GOSS
$83.2M
– –
-2,720,000
Closed -$8.43M
KPTI icon
59
Karyopharm Therapeutics
KPTI
$44M
– –
-930,000
Closed -$6.84M
RAPT
60
DELISTED
RAPT Therapeutics
RAPT
– –
-150,000
Closed -$213K
SLN
61
Silence Therapeutics
SLN
$836M
– –
-78,926
Closed -$480K
VTYX
62
DELISTED
Ventyx Biosciences
VTYX
– –
-251,932
Closed -$2.27M
ZYME icon
63
Zymeworks
ZYME
$2.07B
– –
-108,929
Closed -$2.87M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2026 Portfolio in Review

As of Q1 2026, Opaleye Management held 63 positions worth $759M, up 0.18% from $758M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Opaleye Management withdrew a net $40.4M in Q1 2026, closing 9 positions and reducing 13 holdings. Its most notable exit was Alkermes, an estimated $13.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Editas Medicine worth $4.76M.

  • Opaleye Management's largest Q1 2026 buy was Editas Medicine: 1,926,997 shares worth $4.76M.
  • Opaleye Management added most to UroGen Pharma in Q1 2026, an estimated $23.3M increase.
  • Opaleye Management's biggest Q1 2026 reduction was Harrow, cutting an estimated $47.2M.
  • Opaleye Management fully exited Alkermes in Q1 2026, selling an estimated $13.7M.
  • Opaleye Management's ten largest holdings make up 61% of its $759M portfolio in Q1 2026.
  • Opaleye Management opened 9 new positions and closed 9 in Q1 2026.
  • Opaleye Management's portfolio value rose 0.18% quarter-over-quarter to $759M.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.